EWM
HOWL icon

Evercore Wealth Management’s Werewolf Therapeutics HOWL Stock Holding History

Evercore Wealth Management’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-46,500
Closed -$205K – 410
2022
Q1 		$205K Buy
46,500
+25,000
+116% +$175K ﹤0.01% 415
2021
Q4 		$256K Hold
21,500
– – ﹤0.01% 388
2021
Q3 		$369K Hold
21,500
– – 0.01% 326
2021
Q2 		$375K Buy
+21,500
New +$295K 0.01% 332

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Evercore Wealth Management's HOWL Position: Q2 2022 in Review

Evercore Wealth Management sold out of Werewolf Therapeutics (HOWL) in Q2 2022, closing a stake of 46,500 shares — an estimated $205K sold.

Evercore Wealth Management first reported a position in HOWL in Q2 2021 and held it in 4 quarters. The position peaked at $375K in Q2 2021. 46 funds tracked by Wall St. Rank hold HOWL as of Q2 2022.

  • Evercore Wealth Management reported no remaining Werewolf Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Evercore Wealth Management sold 46,500 Werewolf Therapeutics shares in Q2 2022, an estimated $205K.
  • Evercore Wealth Management first reported a position in Werewolf Therapeutics in Q2 2021 and held it in 4 quarters.
  • Evercore Wealth Management's Werewolf Therapeutics position peaked at $375K in Q2 2021.
  • 46 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2022.

Based on Evercore Wealth Management's 13F filing for Q2 2022, filed 15 Aug 2022.